本文關(guān)鍵詞：參芪扶正注射液聯(lián)合常規(guī)用藥治療心力衰竭的系統(tǒng)評(píng)價(jià)，由筆耕文化傳播整理發(fā)布。

參芪扶正注射液聯(lián)合常規(guī)用藥治療心力衰竭的系統(tǒng)評(píng)價(jià)

Parenterally administered Shenqi Fuzheng for heart failure： a systematic review and Meta-analysis

[1] [2] [3] [4] [5] [6]

SHEN Hao , AI Qing-hua , XIE Yan-ming, HAO Yang, HU Jing , ZHANG Yue-lun （ 1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

[1]中國(guó)中醫(yī)科學(xué)院中醫(yī)臨床基礎(chǔ)醫(yī)學(xué)研究所,北京100700; [2]中國(guó)中醫(yī)科學(xué)院針灸研究所,北京100700; [3]北京大學(xué)公共衛(wèi)生學(xué)院流行病與衛(wèi)生統(tǒng)計(jì)系,北京100191

文章摘要：目的：系統(tǒng)評(píng)價(jià)參芪扶正注射液聯(lián)合常規(guī)用藥治療心力衰竭的有效性和安全性。方法：計(jì)算機(jī)檢索Cochrane圖書館（2013年第2期），Medline（1950～2013．2），EMbase（1980～2013．2），中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM，1978～2013．2），中國(guó)科技期刊全文數(shù)據(jù)庫(kù)（VIP，1989～2013．2），中國(guó)期刊全文數(shù)據(jù)庫(kù)（CNKI，1995～2013．2）萬方數(shù)據(jù)庫(kù)（1990—2013．2），，納入有關(guān)參芪扶正注射液治療心力衰竭的隨機(jī)對(duì)照試驗(yàn)，根據(jù)Cochrane手冊(cè)“對(duì)隨機(jī)對(duì)照試驗(yàn)偏倚風(fēng)險(xiǎn)的評(píng)估工具（Version5．1．0）”對(duì)納入的研究進(jìn)行方法學(xué)質(zhì)量評(píng)價(jià)，并使用RevMan5．2．4軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果：共納入21個(gè)隨機(jī)對(duì)照試驗(yàn)，共1829名受試者，均為低質(zhì)量研究。Meta分析結(jié)果顯示：參芪扶正注射液聯(lián)合常規(guī)用藥在治療一t5力衰竭的患者的臨床療效[OR=3．91，95％C1（2．63，5．83）]，提高左室射血分?jǐn)?shù)（LVEF）[MD=0．08，95％C1（0．05，0．12）]，每搏輸出量（SV）[MD=9．42，95％C1（6．61，12．22）]，心臟指數(shù)（CI）[MD=0．60，95％C1（0．46，0．73）]，心輸出量（CO）[MD：0．98，95％C1（0．61，1．36）]，降低腦力肽濃度（BNP）[MD=-139．05，95％C1（-211．08，-67．02）]方面優(yōu)于常規(guī)治療。治療期間參芪扶正注射液聯(lián)合常規(guī)用藥組未見明顯不良反應(yīng)／事件。結(jié)論：現(xiàn)有臨床證據(jù)表明西醫(yī)常規(guī)用藥的基礎(chǔ)上加用參芪扶正注射液可以提高治療心力衰竭的療效，但由于本系統(tǒng)評(píng)價(jià)納入研究質(zhì)量較低，增加了該次系統(tǒng)評(píng)價(jià)結(jié)論產(chǎn)生偏倚的風(fēng)險(xiǎn)，因此參芪扶正注射液治療心力衰竭療效和安全性需要更多高質(zhì)量臨床試驗(yàn)加以證實(shí)。

Abstr：Objective： To assess the efficacy and safety of parenterally administered Shenqi Fuzheng for heart failure. Method： We searched for all clinical studies, up to February 2013, of parenterally administered Shenqi Fuzheng in the Cochrane library, Medline, EMbase, CBM, CNKI, VIP and Wanfang. Quality assessment and information extraction was completed and screened by two independent reviewers. The quality of the included studies was evaluated according to the Cochrane collaboration＇s tool for assessing risk of bias and allocation concealment. Revman 5.2.4 software was used for data analysis. Result： A total of 21 randomized con- trolled trials were included in this systematic review, all of them were of low quality. Meta-analysis showed that the group receiving par- enterally administered Shenqi Fuzheng in addition to conventional treatment had better therapeutic effectiveness rates than the conven- tional treatment group [ OR = 3.91, 95 % C1 （2.63,5.83） ], with enhanced LVEF [ MD = 0.08,95 % C1 （0.05,0.12） ], S~ [ MD = 9.42, 9 5% C1（6.61,12.22） ], CI [MD =0.60,95%C1（0.46,0.73） ], CO [MD =0.98,95% C1（0.61,1.36） ], reduced BNP [ MD = - 139.05, 95% C1 （ - 211.08, - 67.02 ） ]. The ADR/ADE information of parenterally administered Shenqi Fuzheng in all studies showed that the symptoms of ADR/ADE were mild. Conclusion： Conclusions from this review may have a high risk of bias due to the low quality of thestudies. Hence, reliable conclusions cannot be drawn about the efficacy of parenterally administered Shenqi Fuzheng in the treatment of heart failure. More trials of high quality are required.

文章關(guān)鍵詞：

Keyword：:parenterally administered Shenqi Fuzheng heart failure systematic review

課題項(xiàng)目：國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)（2009ZX09502-030）;中國(guó)中醫(yī)科學(xué)院客座研究員聯(lián)合創(chuàng)新研究項(xiàng)目（ZZ070817）;中國(guó)中醫(yī)科學(xué)院第7批自主選題項(xiàng)目（Z0255）

  本文關(guān)鍵詞：參芪扶正注射液聯(lián)合常規(guī)用藥治療心力衰竭的系統(tǒng)評(píng)價(jià)，由筆耕文化傳播整理發(fā)布。